Published in Oncoimmunology on April 25, 2014
The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med (2015) 1.44
Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2016) 1.26
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07
Combinations of immunotherapy and radiation in cancer therapy. Front Oncol (2014) 1.01
Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 0.98
The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. Oncotarget (2015) 0.95
Is tumor (R)ejection by the immune system the "5th R" of radiobiology? Oncoimmunology (2014) 0.94
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine (2015) 0.92
The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle (2015) 0.91
Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. Oncotarget (2015) 0.89
First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology (2015) 0.88
Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. Nat Rev Clin Oncol (2016) 0.88
Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood (2016) 0.86
Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park) (2015) 0.85
Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84
Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation. Front Oncol (2016) 0.83
Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer (2016) 0.81
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer (2016) 0.81
Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer (2016) 0.80
Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer (2015) 0.79
Nanoelectroablation of Murine Tumors Triggers a CD8-Dependent Inhibition of Secondary Tumor Growth. PLoS One (2015) 0.79
STAT3 inhibition for cancer therapy: Cell-autonomous effects only? Oncoimmunology (2016) 0.78
Radiation takes its Toll. Cancer Lett (2015) 0.78
Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation. Front Oncol (2015) 0.78
Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy. Int J Radiat Oncol Biol Phys (2015) 0.78
Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology (2015) 0.77
Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. Oncology (Williston Park) (2015) 0.77
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer. Oncotarget (2016) 0.77
Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther (2016) 0.77
SjHSP70, a recombinant Schistosoma japonicum heat shock protein 70, is immunostimulatory and induces protective immunity against cercarial challenge in mice. Parasitol Res (2015) 0.76
Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. Cancer Immunol Immunother (2014) 0.76
The in vitro immunogenic potential of caspase-3 proficient breast cancer cells with basal low immunogenicity is increased by hypofractionated irradiation. Radiat Oncol (2015) 0.76
The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia. Oncoimmunology (2016) 0.76
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med (2015) 0.76
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med (2016) 0.76
Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. Transl Lung Cancer Res (2017) 0.76
Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer. Oncoimmunology (2016) 0.75
Alpha Particles Induce Autophagy in Multiple Myeloma Cells. Front Med (Lausanne) (2015) 0.75
Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors. Oncotarget (2016) 0.75
Barriers to Radiation-Induced In Situ Tumor Vaccination. Front Immunol (2017) 0.75
Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol (2017) 0.75
Calreticulin and type I interferon: An unsuspected connection. Oncoimmunology (2017) 0.75
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight (2016) 0.75
The Immunoregulatory Potential of Particle Radiation in Cancer Therapy. Front Immunol (2017) 0.75
The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database. Oncotarget (2017) 0.75
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl Lung Cancer Res (2017) 0.75
Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection. Front Oncol (2017) 0.75
Immune recognition of irradiated cancer cells. Immunol Rev (2017) 0.75
Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization. Front Oncol (2017) 0.75
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Action of x-rays on mammalian cells. J Exp Med (1956) 13.53
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res (1988) 9.96
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res (2009) 4.58
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 4.29
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Systemic effects of local radiotherapy. Lancet Oncol (2009) 2.97
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene (2009) 2.74
Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ (2007) 2.58
Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One (2008) 2.51
An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res (2013) 2.30
Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res (2010) 2.29
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
Molecular characteristics of immunogenic cancer cell death. Cell Death Differ (2007) 1.92
The HaloTag: a novel technology for cell imaging and protein analysis. Methods Mol Biol (2007) 1.90
Chemotherapy induces ATP release from tumor cells. Cell Cycle (2009) 1.83
A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol Biol Cell (2005) 1.80
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol (2011) 1.80
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene (2010) 1.75
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med (2012) 1.63
The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol (2012) 1.24
Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology (2012) 1.16
Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci (2010) 1.16
How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev (2011) 1.15
Calreticulin, a multifunctional Ca2+ binding chaperone of the endoplasmic reticulum. Biochem Cell Biol (1998) 1.10
Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol (2003) 1.07
The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Front Physiol (2013) 1.07
Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med (Berl) (2007) 1.06
Effects of chemoradiation on tumor-host interactions: the immunologic side. J Clin Oncol (2008) 1.00
Differences in estimates of cisplatin-induced cell kill in vitro between colorimetric and cell count/colony assays. In Vitro Cell Dev Biol Anim (2007) 0.84
[Contributions of immunogenic cell death to the efficacy of anticancer chemotherapy]. Bull Mem Acad R Med Belg (2011) 0.79
Resistance to radio- and chemotherapy and the tumour microenvironment. Int J Radiat Biol (2009) 0.78
Is tumor (R)ejection by the immune system the "5th R" of radiobiology? Oncoimmunology (2014) 0.94